Bio-IT World News
YouTube Facebook LinkedIn TwitterInstagram rss
a-divisiion-of-chi
  • Subscribe
  • News
    • Latest News
    • View Press Releases
    • Post a Press Release
    • Reprint Articles
  • Podcast
  • Advertise
    • Media Kit
    • Digital Advertising
    • Lead Generation
    • Editorial Calendar
    • Webinars
    • Whitepapers
    • Podcasts
    • View Press Releases
    • Post a Press Release
  • Free Downloads
    • Whitepapers
    • Podcasts
    • Webinars
    • Inside eBooks
  • Events
    • Webinars
    • Industry Events
    • IT Conferences
    • Bio-IT World Expo
    • Bio-IT World Expo Europe
  • About Us
    • Editorial Profile
    • Editorial Calender
    • Contact Us
    • Submit a story
    • Innovative Practices Awards
    • Linking Policy
  • Bio-IT World Expo
    • Bio-IT World Boston
    • Bio-IT World Europe
 
 
 
 
  • Owkin Announces First Patient Dosed in Phase I AI-optimized Clinical Trial of OKN4395, a First-in-Class EP2/EP4/DP1 Triple Inhibitor for Patients with Solid Tumors

    Feb 3, 2025, 09:53 AM by
    Full story
  • Zymo Research Launches Microbiome Grant to Support Innovation in Microbial Sciences

    Feb 3, 2025, 09:53 AM by
    Zymo Research is proud to introduce the Master the Microbiome Grant, a global initiative dedicated to advancing research in microbiomics, metagenomics, and microbial sciences.
    Full story
  • Redefining Storage to Enable Digital Twins

    Jan 30, 2025, 01:00 AM by User Not Found
    Bio-IT World | While the concept of digital twins is similar in life sciences to manufacturing, human bodies are significantly more complex than industrial machines and systems, amplifying the challenges surrounding data generation, management, and analysis. Making effective use of the data required to advance digital twin research creates immense infrastructure challenges.
    Full story
  • Follow the Money: Obesity, COPD, Universal AI for Biology

    Jan 29, 2025, 01:00 AM by User Not Found
    Bio-IT World | January saw new company launches in COPD and small molecules, as well as investments targeting genetic engineering, epigenome editing, regenerative medicine, and more.
    Full story
  • GSK’s $1B Acquisition, Roche Licenses Gene Therapy, New Products, More

    Jan 28, 2025, 01:00 AM by User Not Found
    Bio-IT World | 23andMe launches a new research offering after mass resignation by their board, new multi-omics tool from Enhanc3D Genomics, Absci and Owkin announce an AI partnership, a new cloud-based vivarium platform from Charles River, and more.
    Full story
  • Radio Frequencies Show Potential in Treating Alzheimer’s Disease

    Jan 23, 2025, 01:00 AM by User Not Found
    Bio-IT World | Through a fortunate stroke of serendipity 15 years ago, researchers experimenting with a mouse model of Alzheimer’s disease found that radio frequency (RF) energy could improve cognitive health. It was not unlike the discovery of penicillin based on the unexpected appearance of a bacteria-killing mold in a petri dish.
    Full story
  • Mount Sinai Develops AI Prediction Tool for Cancer Patient Response to ICI Therapy

    Jan 22, 2025, 01:00 AM by User Not Found
    Bio-IT World | Researchers at the Tisch Cancer Institute at Mount Sinai, in collaboration with Memorial Sloan Kettering Cancer Center (MSKCC), have developed SCORPIO, an artificial intelligence (AI) tool that can predict how well patients with cancer will respond to immune checkpoint inhibitor (ICI) therapy by analyzing routine blood tests and clinical data.
    Full story
  • PacBio at JPM: Portfolio Development, LDTs

    Jan 21, 2025, 01:00 AM by User Not Found
    Bio-IT World | PacBio’s president Christian Henry gave the sequencing company’s 43rd Annual J.P. Morgan Healthcare Conference address last week. And while Oxford Nanopore and Illumina both doubled down on proteomics and a multi-omic future, Henry stayed focus on PacBio’s mission to enable the promise of genomics to better human health.
    Full story
  • Cellular Origins and Cytiva are collaborating to deliver automated robotic manufacturing capabilities for cell and gene therapies

    Jan 17, 2025, 06:59 AM by
    Full story
  • Avalon Healthcare Solutions to Team with Sentara Health Plans to Offer Genetic Testing Management

    Jan 16, 2025, 08:11 AM by
    Avalon Healthcare Solutions to Team with Sentara Health Plans to Offer Genetic Testing Management
    Full story
  • Cotiviti Launches Engagement Hub Solution to Empower Health Plans to Drive Member Outreach

    Jan 16, 2025, 08:11 AM by
    Full story
  • Ambience Healthcare and St. Luke's Health System Partner to Reduce Clinician Burnout and Increase Patient Face Time

    Jan 16, 2025, 08:11 AM by
    Ambience Healthcare, the leading AI platform for healthcare documentation, scribing, coding, CDI, and patient summaries, announced today a pilot study with St. Luke's Health System has resulted in a 25% reduction in clinician burnout and a nearly 23% increase in patient face time for clinicians.
    Full story
  • Illumina at JPM: Multi-Omics, Constellation, Partnerships

    Jan 16, 2025, 01:00 AM by User Not Found
    Bio-IT World | Jacob Thaysen gave Illumina’s annual presentation at the 43rd Annual J.P. Morgan Healthcare Conference yesterday, outlining Illumina’s early 2024 results and the vision for the future. Illumina is not focusing only on building sequencers and sequencing genomes. Thaysen outlined an M&A and partnership strategy focused on expanding the company’s addressable markets.
    Full story
  • University Medical Centre Ljubljana and University Hospital of Maribor Elevate Antimicrobial Stewardship with DoseMeRx

    Jan 15, 2025, 08:41 AM by
    DoseMe, a leader in model-informed precision dosing (MIPD), announced the University Medical Centre Ljubljana and University Hospital of Maribor have implemented DoseMeRx, an innovative therapeutic drug monitoring (TDM) platform. This marks a significant advancement in antimicrobial stewardship in Slovenia.
    Full story
  • Oxford Nanopore at JPM: A Proteomics-Genomics Thing of Beauty

    Jan 15, 2025, 01:00 AM by User Not Found
    Bio-IT World | Gordon Sanghera, CEO, presented on behalf of Oxford Nanopore Technologies at the 43rd Annual J.P. Morgan Healthcare Conference this week in San Francisco. Sanghera led the major sequencing companies in position on the program, presenting on Monday a multi-omics and proteomics emphasis that was echoed throughout the week by other sequencing platform providers.
    Full story
  • Proscia’s Growth More Than Doubles As Customers Adopt Enterprise Pathology

    Jan 14, 2025, 08:17 AM by
    Record year comes as the rise of precision medicine drives a surge in demand
    Full story
  • Integrated DNA Technologies Names Ajay Gannerkote as New President to Lead Bold Era of Innovation and Growth

    Jan 14, 2025, 08:17 AM by
    Ajay Gannerkote, an experienced healthcare leader with more than 20 years of demonstrated success driving industry growth and transformation, takes helm at global genomics company
    Full story
  • Exploring Muscle Clues in Chronic Fatigue Syndrome and Long COVID

    Jan 14, 2025, 01:00 AM by User Not Found
    Bio-IT World | An international team of researchers is delving into the molecular and cellular changes in muscle tissue associated with Chronic Fatigue Syndrome (CFS) and long COVID. The effort focuses on identifying biomarkers and pathways that could pave the way for diagnosis and treatment.
    Full story
  • Illumina Joins NVIDIA’s Agentic AI Vision at J.P. Morgan Healthcare Conference

    Jan 13, 2025, 09:00 AM by User Not Found
    Bio-IT World | Among the many partnerships and technical announcements made by NVIDIA during the company's Monday morning presentation at the 43rd Annual J.P. Morgan Healthcare Conference, NVIDIA focused several on innovation within the healthcare and life sciences industry.
    Full story
  • Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery

    Jan 13, 2025, 08:15 AM by
    Collaboration combines Owkin’s novel AI target discovery and agentic AI expertise with Absci’s leading AI de novo design models to accelerate the discovery and design of potential first-in-class therapeutics
    Full story
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9 (current)
  • 10
  • »
 
CHI | Cambridge HealthTech Institute

250 First Avenue, Suite 300
Needham, MA 02494

P: 781.972.5400
F: 781.972.5425
E: chi@healthtech.com

Life Science Portals

Biological Therapeutic Products

Biomarkers & Diagnostics

Biopharma Strategy

Bioprocess & Manufacturing

Chemistry

Clinical Trials &
Translational Medicine

Drug & Device Safety

Drug Discovery & Development

Drug Targets

Healthcare

IT, AI, ML & Informatics

Technology & Tools For
Life Science

Therapeutic Indications

Venture, Innovation & Partnering

CHI Divisions

Conferences

Reports & Market Research

Barnett Educational Services

News & Advertising

Professional Services

Corporate Information

Cambridge Innovation
Institute

Executive Team

Testimonials

Mailing List

Careers


Request Information

Privacy Policy